Port Business Incubator

Incubating successful startups means more than giving them a space to grow



Finding flexible and affordable space can be an important step in the formation and growth of a successful company. Equally important is being located in an environment with a “critical mass” of entrepreneurs, innovators and sources of capital. Our world-class Port business incubator is one of only a handful of incubators in the region offering turnkey office and lab facilities, as well as access to shared lab equipment that is often too expensive for an early-stage company to purchase on its own. Beyond the physical infrastructure, the Port offers a strong connection to Greater Philadelphia’s innovation ecosystem and the ingredients startups need to grow and be successful. Residents can access Science Center networks and programs to capitalize and develop their businesses, while tapping into the rich pool of local talent to grow their workforce.  


incubator residents


in private capital raised by Port companies since 2012


in government funding raised by Port residents since 2012

Our Companies

Home to a diverse group of early-stage companies in life sciences and emerging technologies, the Port business incubator at the Science Center in Philadelphia is often a startup’s first stop on its path to growth. Our residents are shaping the future of healthcare, energy, technology and beyond.






Creating humanized rabbits as an antibody discovery platform. This platform offers major improvement potential in diversity and affinity over existing mouse antibody discovery platforms.


AUM Biotech
A biotech startup developing gene-targeting molecules that can be used for research and personalized medicine for a variety of rare diseases, cancers, and infectious diseases.


AUM Life Science 


Chimeron Bio


Chondrial Therapeutics

Developing a novel protein replacement strategy for treating mitochondrial diseases in patients. This technology will have broad application, should the company be successful in demonstrating activity in treating Friedreich’s Ataxia - a rare debilitating condition in which children and young adults progressively lose the ability to walk and speak as their hearts grow thick and weak before they eventually fail.



Solving a major process bottleneck in therapeutic protein production while significantly lowering the cost of goods for biotech and contract manufacturing companies. Our mission is to provide robust, flexible and cost-effective continuous manufacturing solutions to the biopharm industry using our proprietary CCTC technology platform.


Developing a blood test for the rapid diagnosis of epilepsy. This blood test differentiates

epilepsy from other causes of seizures, sparing patients from unnecessary tests and inappropriate treatments.


Hyalo Technologies
Establishing a next-generation nanotechnology drug delivery system that will reduce drug side effects and increase patient compliance. Hyalo accomplishes this by target-specific drug delivery, time-controlled drug release, sequential drug delivery intelligence and 100% biodegradability.


InnaMed, Inc.

InnaMed allows doctors and nurses to take a more intimate, data-driven approach to caring for you by enabling you to perform frequent blood tests at home.



Creates opportunities for low-income students by increasing their interest and exposure to Science, Technology, Engineering, and Mathematics (STEM) disciplines through inquiry- and project-based learning.


Kira Pharmaceutical


Lenima Field Diagnostic
Creating a point-of–care diagnostic test for infectious diseases in the gastrointestinal tract, blood stream, and respiratory tract. The test menu also includes novel cancer markers for screening high-risk individuals.


Developing a small molecule therapy to reduce side effects and increase effectiveness of radiation treatment for cancer. Synthesized from natural flaxseed, it has been shown to enhance chemotherapy and radiation treatment while protecting normal tissue from damage.


Developing a first-in-class small molecule cancer therapy. Targeting the most potent suppressor pathways in human cancer, its lead drug candidate, ONC201, is in clinical trials for multiple cancer indications.


Persistent Telecom Solutions
Developing and offering products and services for network service providers to manage network performance, service and reporting, and to predict faults and service level breaches.


Persona Partners
Helps companies develop brands that symbolize the values and ideals espoused by their target consumers. Driven by robust data analytics, the client brand comes to represent an identity that customers aspire to represent themselves.


Quatitative Radiology Solutions

Offers advanced body-wide quantification of medical images for applications in radiology, radiation oncology, and medical oncology. Its unique Automatic Anatomy Recognition (AAR) system supports recognition and delineation of anatomical objects and diseased tissue in multiple body regions in MRI, CT, and PET/CT images.


RSC Worldwide
A subsidiary of the UK-based Royal Society of Chemistry, the company's main purpose is to help promote chemical science activities in North America.


SAB Technology
Generates protein particles that contain DNA to be delivered to cells with genetic defects, which could potentially correct the defects.


Developing a small molecule therapy that inhibits the metabolic process in cancer cells to treat patients with solid tumors such as pancreatic cancer.



A biotech startup whose primary mission is to discover and develop small molecule therapeutics to treat chronic viral infections and its associated diseases, including cancer and autoimmunity.  Its secondary mission is to exploit viral latency to develop improved vectors for gene therapy and vaccine purposes.



The Port is a turn-key facility catering to the flexible leasing needs of startup companies. Residents may select from a combination of fully furnished offices, cubicles, and wet and dry labs. Port staff leverages established networks to identify area resources that can help resident companies to grow and flourish.

All-inclusive with the Port’s easy-to-manage fee are: 

  • Rent and utilities
  • Furniture and VOIP phone 
  • 24/7 access
  • On-site security
  • Internet connectivity and on-site IT support
  • Individual laboratory suites furnished with benches, casework, chemical hood, and built-in safety features such as safety shower and eye-wash station
  • Shared scientific equipment including autoclave, cold room, glassware washer, de-ionized water, centrifuges and other laboratory instruments
  • Mail, copy and fax facilities 
  • Access to kitchen and cyber café areas
  • Basic cleaning and maintenance
  • Access to conference rooms, event space and shared receptionist services
  • Marketing and public relations assistance 
  • Connectivity with regional funding organizations, angel groups and venture capital firms
  • Guidance in strategic partnership development
  • Promotion to government agencies and policy makers

3675 Market Street 

A partnership to serve and strengthen entrepreneurship in Philadelphia.


Just as our resident companies experiment and innovate, the Science Center is innovating and iterating as well. Specifically, we’re taking our support for business incubation to the next level as we plan to move into our new building in 3675 Market Street in Summer 2018.


We’re partnering with globally recognized companies CIC and BioLabs to provide world-class office and lab facilities for startups at our new location in 3675 Market Street. This partnership will provide a significant boost for resident companies of the Science Center’s Port business incubator.

Companies will be able to take advantage of first-class lab and office facilities, premium shared equipment, a higher level of concierge services and access to CIC and BioLabs’ global networks – as well as access to the Science Center’s nationally recognized commercialization and accelerator programs that are focused on mentoring, funding, strategy development and resources to accelerate businesses. Together, we’re taking entrepreneurship and innovation to the next level. Join us.


The Port will remain open until the new building is complete, ensuring a seamless transition for resident companies. To learn more about CIC and BioLabs’ facilities in 3675 Market, click here